Alligator Bioscience AB (publ) (STO:ATORX)

Market Cap	112.25M -11.6%
Revenue (ttm)	46.22M +66.4%
Net Income	-77.72M
EPS	-4.70
Shares Out	534.52M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,774,214
Average Volume	5,713,653
Open	0.2189
Previous Close	0.2100
Day's Range	0.1972 - 0.2189
52-Week Range	0.1700 - 225.0000
Beta	1.17
RSI	39.33
Earnings Date	Feb 12, 2026

About Alligator Bioscience AB

Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Finland and Sweden. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 2 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage for the treatment of solid metastatic tumors. It also offers...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 13
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ATORX

Financial Performance

In 2024, Alligator Bioscience AB's revenue was 57.72 million, a decrease of -2.58% compared to the previous year's 59.25 million. Losses were -233.89 million, -5.91% less than in 2023.